Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific BCRP inhibitor.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 3,140 | 6-8周 | ||
100 mg | ¥ 4,760 | 6-8周 |
YHO-13351 的其他形式现货产品:
产品描述 | YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific BCRP inhibitor. |
体外活性 | YHO-13177 enhances SN-38, mitoxantrone and topotecan in BCRP transduced human colon cancer HCT116 (HCT116/BCRP) cells and BCRP-expressing SN-38 resistant human lung cancer A549 (A549/SN4) Cytotoxicity in cells, but little effect on parental cells. In addition, YHO-13177 potentiates the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. YHO-13177 increases the intracellular accumulation of Hoechst 33342, a substrate of BCRP, at 30 minutes and partially suppresses the expression of BCRP protein at more than 24 hours after its treatment in both HCT116/BCRP and A549/SN4 cells . |
体内活性 | YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration In mice. Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models . |
分子量 | 579.73 |
分子式 | C27H37N3O7S2 |
CAS No. | 1346753-00-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 38 mg/mL (65.55 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7249 mL | 8.6247 mL | 17.2494 mL | 43.1235 mL |
5 mM | 0.345 mL | 1.7249 mL | 3.4499 mL | 8.6247 mL | |
10 mM | 0.1725 mL | 0.8625 mL | 1.7249 mL | 4.3124 mL | |
20 mM | 0.0862 mL | 0.4312 mL | 0.8625 mL | 2.1562 mL | |
50 mM | 0.0345 mL | 0.1725 mL | 0.345 mL | 0.8625 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
YHO-13351 1346753-00-1 Chromatin/Epigenetic Epigenetic Reader Domain YHO 13351 YHO13351 Inhibitor inhibitor inhibit